Nuclear trafficking and functions of endocytic proteins implicated in oncogenesis

Traffic

Volumn 10, Issue 9, 2009, Pages 1209-1220

  Borlido, Joana ^a   Zecchini, Vincent ^a   Mills, Ian G ^a  

^a CRUK Cambridge Research Institute   (United Kingdom)

Author keywords

Adaptor; Clathrin; Endocytosis; Network; Signalling; Transcription

Indexed keywords

ADAPTOR PROTEIN; BETA ARRESTIN 1; BETA ARRESTIN 2; CLATHRIN ASSEMBLY LYMPHOID MYELOID LEUKEMIA PROTEIN; CLATHRIN ASSEMBLY PROTEIN; DISABLED PROTEIN 1; DISABLED PROTEIN 2; ENDOCYTIC ADAPTOR PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15; EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15 RELATED; EPSIN; EPSIN 1; HUNTINGTIN; HUNTINGTIN INTERACTING PROTEIN 1; MEMBRANE PROTEIN; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL MIGRATION; CELL ONCOGENE; CELL PROLIFERATION; ENDOCYTOSIS; GENE EXPRESSION; GENE FUSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GENE;

ACTIVE TRANSPORT, CELL NUCLEUS; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; CELL NUCLEUS; CYTOPLASM; ENDOCYTOSIS; ENDOSOMES; HUMANS; NEOPLASMS;

EID: 68549111215     PISSN: 13989219     EISSN: 16000854     Source Type: Journal    
DOI: 10.1111/j.1600-0854.2009.00922.x     Document Type: Review

References (94)

1. Kirchhausen T. Clathrin. Annu Rev Biochem 2000;69:699-727.
2. Bonifacino JS, Lippincott-Schwartz J. Coat proteins: Shaping membrane transport. Nat Rev 2003;4:409-414.
3. Glebov OO, Nichols BJ. Distribution of lipid raft markers in live cells. Biochem Soc Trans 2004;32:673-675.
4. Nichols B. Caveosomes and endocytosis of lipid rafts. J Cell Sci 2003;116:4707-4714.
5. Nichols BJ, Lippincott-Schwartz J. Endocytosis without clathrin coats. Trends Cell Biol 2001;11:406-412.
6. Crowther RA, Pearse BM. Assembly and packing of clathrin into coats. J Cell Biol 1981;91:790-797.
7. Pearse BM, Crowther RA. Packing of clathrin into coats. Cold Spring Harb Symp Quant Biol 1982;46:703-706.
8. Hanover JA, Willingham MC, Pastan I. Kinetics of transit of transferrin and epidermal growth factor through clathrin-coated membranes. Cell 1984;39:283-293.
9. Vieira AV, Lamaze C, Schmid SL. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996;274:2086-2089.
10. McMahon HT, Mills IG. COP and clathrin-coated vesicle budding: Different pathways, common approaches. Curr Opin Cell Biol 2004;16:379-391.
11. Di Fiore PP, De Camilli P. Endocytosis and signaling an inseparable partnership. Cell 2001;106:1-4.
12. Floyd S, De Camilli P. Endocytosis proteins and cancer: A potential link? Trends Cell Biol 1998;8:299-301.
13. Hyun TS, Ross TS. HIP1: Trafficking roles and regulation of tumorigenesis. Trends Mol Med 2004;10:194-199.
14. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005;65:338-348.
15. Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, Sanda MG, Ross TS. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 2002;110:351-360.
16. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-2053.
17. Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus MH, Muraro R. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 2004;204:317-325.
18. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005;65:1384-1393.
19. Stewart M, Baker RP, Bayliss R, Clayton L, Grant RP, Littlewood T, Matsuura Y. Molecular mechanism of translocation through nuclear pore complexes during nuclear protein import. FEBS Lett 2001;498:145-149.
20. Harel A, Forbes DJ. Importin beta: Conducting a much larger cellular symphony. Mol Cell 2004;16:319-330.
21. Poon IK, Jans DA. Regulation of nuclear transport: Central role in development and transformation? Traffic 2005;6:173-186.
22. Clarke PR, Zhang C. Spatial and temporal control of nuclear envelope assembly by Ran GTPase. Symp Soc Exp Biol 2004;56:193-204.
23. Kutay U, Guttinger S. Leucine-rich nuclear-export signals: Born to be weak. Trends Cell Biol 2005;15:121-124.
24. Yashiroda Y, Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003;10:741-748.
25. Hyman J, Chen H, Di Fiore PP, De Camilli P, Brunger AT. Epsin 1 undergoes nucleocytosolic shuttling and its eps15 interactor NH(2)-terminal homology (ENTH) domain, structurally similar to Armadillo and HEAT repeats, interacts with the transcription factor promyelocytic leukemia Zn(2)+ finger protein (PLZF). J Cell Biol 2000;149:537-546.
26. Poupon V, Polo S, Vecchi M, Martin G, Dautry-Varsat A, Cerf-Bensussan N, Di Fiore PP, Benmerah A. Differential nucleocytoplasmic trafficking between the related endocytic proteins Eps15 and Eps15R. J Biol Chem 2002;277:8941-8948.
27. Wang P, Wu Y, Ge X, Ma L, Pei G. Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem 2003;278:11648-11653.
28. Ma L, Pei G. Beta-arrestin signaling and regulation of transcription. J Cell Sci 2007;120:213-218.
29. Ge L, Ly Y, Hollenberg M, DeFea K. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. J Biol Chem 2003;278:34418-34426.
30. Wei H, Ahn S, Barnes WG, Lefkowitz RJ. Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2. J Biol Chem 2004;279:48255-48261.
31. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001;294:1307-1313.
32. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A, Lefkowitz RJ, Larsson O. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem 2007;282:11329-11338.
33. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, Zhang M, Bao G, Wang F, Zhang X, Yang R, Fan F, Chen X, Pei G, Ma L. A nuclear function of beta-arrestin1 in GPCR signaling: Regulation of histone acetylation and gene transcription. Cell 2005;123:833-847.
34. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 2006;103:1492-1497.
35. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116:2208-2217.
36. Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM. Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2008;180:5699-5706.
37. Zou L, Yang R, Chai J, Pei G. Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis. FASEB J 2008;22:355-364.
38. Winter V, Hauser MT. Exploring the ESCRTing machinery in eukaryotes. Trends Plant Sci 2006;11:115-123.
39. Bishop N, Horman A, Woodman P. Mammalian class E vps proteins recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates. J Cell Biol 2002;157:91-101.
40. Lu Q, Hope LW, Brasch M, Reinhard C, Cohen SN. TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc Natl Acad Sci U S A 2003;100:7626-7631.
41. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006;99:362-372.
42. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28:778-808.
43. Burgdorf S, Leister P, Scheidtmann KH. TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. J Biol Chem 2004;279:17524-17534.
44. Sun Z, Pan J, Hope WX, Cohen SN, Balk SP. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer 1999;86:689-696.
45. Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP, Garabedian MJ. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 1999;18:5380-5388.
46. Ismaili N, Blind R, Garabedian MJ. Stabilization of the unliganded glucocorticoid receptor by TSG101. J Biol Chem 2005;280:11120-11126.
47. Xie W, Li L, Cohen SN. Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc Natl Acad Sci U S A 1998;95:1595-1600.
48. Zhong Q, Chen Y, Jones D, Lee WH. Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 1998;58:2699-2702.
49. Hyun TS, Rao DS, Saint-Dic D, Michael LE, Kumar PD, Bradley SV, Mizukami IF, Oravecz-Wilson KI, Ross TS. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. J Biol Chem 2004;279:14294-14306.
50. Mishra SK, Agostinelli NR, Brett TJ, Mizukami I, Ross TS, Traub LM. Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins. J Biol Chem 2001;276:46230-46236.
51. McPherson PS. The endocytic machinery at an interface with the actin cytoskeleton: A dynamic, hip intersection. Trends Cell Biol 2002;12:312-315.
52. Mills IG, Gaughan L, Robson C, Ross T, McCracken S, Kelly J, Neal DE. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol 2005;170:191-200.
53. Jasavala R, Martinez H, Thumar J, Andaya A, Gingras AC, Eng JK, Aebersold R, Han DK, Wright ME. Identification of putative androgen receptor interaction protein modules: Cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells. Mol Cell Proteomics 2007;6:252-271.
54. Vecchi M, Di Fiore PP. It's HIP to be a hub: New trends for old-fashioned proteins. J Cell Biol 2005;170:169-171.
55. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009 Apr 20;27(12):2022-9. Epub 2009 Mar 16.
56. Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan AM, Sanda MG, Ross TS. Serum antibodies to Huntingtin interacting protein-1: A new blood test for prostate cancer. Cancer Res 2005;65:4126-4133.
57. Rao DS, Bradley SV, Kumar PD, Hyun TS, Saint-Dic D, Oravecz-Wilson K, Kleer CG, Ross TS. Altered receptor trafficking in Huntingtin interacting protein 1-transformed cells. Cancer Cell 2003;3:471-482.
58. Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, Ross TS. Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res 2007;67:3609-3615.
59. Chigira S, Sugita K, Kita K, Sugaya S, Arase Y, Ichinose M, Shirasawa H, Suzuki N. Increased expression of the Huntingtin interacting protein-1 gene in cells from Hutchinson Gilford Syndrome (Progeria) patients and aged donors. J Gerontol A Biol Sci Med Sci 2003;58:B873-B878.
60. Bradley SV, Smith MR, Hyun TS, Lucas PC, Li L, Antonuk D, Joshi I, Jin F, Ross TS. Aberrant Huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res 2007;67:8923-8931.
61. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002;10:1107-1117.
62. Hess JL. MLL: A histone methyltransferase disrupted in leukemia. Trends Mol Med 2004;10:500-507.
63. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 2003;4:99-110.
64. Sagawa M, Shimizu T, Shimizu T, Awaya N, Mitsuhashi T, Ikeda Y, Okamoto S, Kizaki M. Establishment of a new human acute monocytic leukemia cell line TZ-1 with t(1;11)(p32;q23) and fusion gene MLL-EPS15. Leukemia 2006;20:1566-1571.
65. Polo S, Confalonieri S, Salcini AE, Di Fiore PP. EH and UIM: Endocytosis and more. Sci STKE 2003;2003:rE17.
66. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998;91:4419-4426.
67. Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci U S A 1996;93:4804-4809.
68. Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: Localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999;10:2687-2702.
69. Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 2006;8:1017-1024.
70. So CW, Caldas C, Liu MM, Chen SJ, Huang QH, Gu LJ, Sham MH, Wiedemann LM, Chan LC. EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia. Proc Natl Acad Sci U S A 1997;94:2563-2568.
71. So CW, So CK, Cheung N, Chew SL, Sham MH, Chan LC. The interaction between EEN and Abi-1, two MLL fusion partners, and synaptojanin and dynamin: Implications for leukaemogenesis. Leukemia 2000;14:594-601.
72. Yam JW, Jin DY, So CW, Chan LC. Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein. Blood 2004;103:1445-1453.
73. Enari M, Ohmori K, Kitabayashi I, Taya Y. Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev 2006;20:1087-1099.
74. Zecchini V, Mills IG. Putting chromatin immunoprecipitation into context. J Cell Biochem 2009 May 1; 107(1):19-29.
75. Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F, Afzal V, Ren B, Rubin EM, Pennacchio LA. ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 2009;457:854-858.
76. Bradley SV, Hyun TS, Oravecz-Wilson KI, Li L, Waldorff EI, Ermilov AN, Goldstein SA, Zhang CX, Drubin DG, Varela K, Parlow A, Dlugosz AA, Ross TS. Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1. Hum Mol Genet 2007;16:1279-1292.
77. Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ. Beta-arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci U S A 2001;98:1601-1606.
78. Benmerah A, Scott M, Poupon V, Marullo S. Nuclear functions for plasma membrane-associated proteins? Traffic (Copenhagen, Denmark) 2003;4:503-511.
79. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res 2004;32:e3.
80. Zhang X, Guo C, Chen Y, Shulha HP, Schnetz MP, LaFramboise T, Bartels CF, Markowitz S, Weng Z, Scacheri PC, Wang Z. Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. Nat Methods 2008;5:163-165.
81. Royle SJ, Bright NA, Lagnado L. Clathrin is required for the function of the mitotic spindle. Nature 2005;434:1152-1157.
82. Carlton JG, Martin-Serrano J. Parallels between cytokinesis and retroviral budding: A role for the ESCRT machinery. Science 2007;316:1908-1912.
83. Scott MG, Le Rouzic E, Perianin A, Pierotti V, Enslen H, Benichou S, Marullo S, Benmerah A. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem 2002;277:37693-37701.
84. Neuhaus EM, Mashukova A, Barbour J, Wolters D, Hatt H. Novel function of beta-arrestin2 in the nucleus of mature spermatozoa. J Cell Sci 2006;119:3047-3056.
85. Archangelo LF, Glasner J, Krause A, Bohlander SK. The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10. Oncogene 2006;25:4099-4109.
86. Vecchi M, Polo S, Poupon V, van de Loo JW, Benmerah A, Di Fiore PP. Nucleocytoplasmic shuttling of endocytic proteins. J Cell Biol 2001;153:1511-1517.
87. Honda T, Nakajima K. Mouse Disabled1 (DAB1) is a nucleocytoplasmic shuttling protein. J Biol Chem 2006;281:38951-38965.
88. Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, Traub LM. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J 2002;21:4915-4926.
89. Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT. The role of DOC-2/ DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer. J Biol Chem 1999;274:31981-31986.
90. He J, Xu J, Xu XX, Hall RA. Cell cycle-dependent phosphorylation of Disabled-2 by cdc2. Oncogene 2003;22:4524-4530.
91. Cho SY, Jeon JW, Lee SH, Park SS. p67 isoform of mouse disabled 2 protein acts as a transcriptional activator during the differentiation of F9 cells. Biochem J 2000;352:645-650.
92. Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 2001;20:2789-2801.
93. Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH. Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J 2003;22:3084-3094.
94. Li L, Liao J, Ruland J, Mak TW, Cohen SN. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci U S A 2001;98:1619-1624.